PolyPid’s CEO and Founder Ramp Up Insider Buying Ahead of FDA‑Dated Antibiotic Push
PolyPid insider stock options and CEO buying signal confidence in FDA‑approved antibiotic D‑PLEX100, boosting investor optimism while highlighting risk‑adjusted valuation.
3 minutes to read